Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
PHASE4CompletedINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
July 31, 2014
Primary Completion Date
August 31, 2015
Study Completion Date
September 30, 2015
Conditions
Hepatitis C InfectionHIV Infection
Interventions
DRUG
Sofosbuvir, Ribavirin, and Stribild
Trial Locations (1)
07102
Saint Michael's Medical Center, Newark
All Listed Sponsors
lead
Saint Michael's Medical Center
OTHER
NCT02220868 - Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study | Biotech Hunter | Biotech Hunter